What this is
- This research investigates the relationship between the FTO rs9939609 genetic variant and () risk in a Palestinian population.
- A total of 399 participants were analyzed, including 281 with and 118 healthy controls.
- The study finds a significant association of the A allele of FTO rs9939609 with increased risk, particularly when adjusted for age and gender.
Essence
- The is associated with an increased risk of type 2 diabetes in the Palestinian population, with an allelic odds ratio of 1.92. This association is partially mediated by body mass index (BMI).
Key takeaways
- The A allele of FTO rs9939609 is associated with a higher risk of , with an allelic odds ratio of 1.92 (95% CI [1.09–3.29], p = 0.02) after adjusting for age and gender.
- When adjusted for BMI, the association remains significant with an odds ratio of 1.84 (95% CI [1.04–3.05], p = 0.03), indicating that the variant's effect on is not entirely mediated by BMI.
- Among diabetic participants, those with the AA genotype had the highest mean BMI (34.11±7.1), suggesting a potential link between the variant and obesity.
Caveats
- The study's sample size of 399 may limit the generalizability of the findings. Larger studies are needed to confirm these associations.
- No significant associations were found between the FTO variant and complications or cardiovascular disease in this population.
- The lack of data on lifestyle factors such as physical activity and diet may impact the interpretation of the variant's role in risk.
Definitions
- FTO rs9939609 variant: A specific genetic polymorphism in the fat-mass and obesity-associated gene linked to obesity and type 2 diabetes risk.
- Type 2 diabetes mellitus (T2DM): A chronic condition characterized by insulin resistance and high blood sugar levels, often associated with obesity.
AI simplified
Background
Type 2 diabetes mellitus (T2DM) is the most common type of diabetes as it accounts for more than 90% of all diabetes cases worldwide (World Health Organization) [1]. Polymorphisms within the fat-mass and obesity-associated gene (FTO) are of particular interest as they have known effect on obesity which is a major risk factor for T2DM. A genome-wide association study (GWAS) conducted in 2007, confirmed that rs9939609 variant located within the first intron of the FTO gene predisposes European populations to diabetes through an effect on body mass index (BMI) [2, 3], while other reports from South Asian population showed that FTO gene variants increase the risk of type 2 diabetes independent of BMI [4]. Since then, several studies represent various ethnic populations, confirmed strong associations of the FTO rs9939609 with obesity [5, 6]. This association was not replicated in the Chinese Han population and African Americans [7, 8]. It is well-established that dyslipidemia is a risk factor for cardiovascular diseases (CVD) in diabetic patients. However, a study conducted by Doney et al. [9] demonstrated that A allele rs9939609 in the FTO gene increases the risk of myocardial infarction in patients with T2DM independent of BMI, glycated hemoglobin, mean arterial pressure and dyslipidemia. Moreover, a significant association of FTO variant was found in Indian patients with T2DM without dyslipidemia [10].
A sex-specific effect of FTO variants on susceptibility to obesity have been shown, a study -in 2016- indicated that the effect of FTO variants on T2DM susceptibility in Japanese men but not women is mediated through FTO effect on BMI [11]. In 2018, a case control study conducted on obese Iranian women showed that several FTO variants including rs9939609 were associated with T2DM and obesity as well [12]. A recent spatial and meta-analysis suggested a region-related associations between FTO rs9939609 and T2DM [13]. Thus, the reported results were not consistent in different ethnic population.
In Palestine, the prevalence of DM (for adults aged > 25 years) was 15.3% in 2010, but estimates have placed to be as high as 20.8% by 2020 [14, 15]. Diabetes and its complications are estimated to account for approximately 5.7% of all deaths in Palestine [16]. The prevalence of overweight and obesity is rapidly escalating in the youth and adults, probably due changes in lifestyle, further enhancing the risk of diabetes. In 2016, a cross sectional study among the students at An-Najah National University in Nablus district (North Palestine) showed that the prevalence of overweight and obesity was 26.2%, with significant increase in males (36.4%) compared to females (19.1%) [17]. Genetic association studies of T2DM among Palestinians are scarce. Two studies conducted by Ereqat and colleagues in 2009 [18, 19] investigated the genetic association of Pro12Ala Polymorphism of the PPAR-Gamma 2 gene and rs7903146 variant in the transcription factor 7 like 2 gene (TCF7L2) with T2DM. However, no studies have been conducted to determine the genetic association of FTO variants with T2DM and/ or obesity. Therefore, our study aimed to examine the association between the FTO rs9939609 SNP with the risk of T2DM and its-related phenotypes in Palestinian population.
Methods
Study population
A total of 399 unrelated individuals were recruited from different cities in Palestine. Two-hundred eighty one cases, aged > 40 years, were diagnosed by T2DM according to WHO criteria based on fasting plasma glucose 126 mg/dl and/or currently being treated with medication for diabetes. All participants were recruited within the period of 2016–2017 in collaboration with UNRWA clinics (Hebron and Ramallah, Palestine). The anthropometric measurements were collected from their medical records that included age, sex, family history, drug history, medical history and other related information.
Fasting blood was collected for biochemical tests and DNA studies. All the cases with probable diagnosis of type 1 diabetes were excluded. The control group (n = 118), was selected from individuals who came to the same clinic for health check-up with no past medical history for T2DM and no family history of diabetes in first-degree relations. Age at examination was > 40 years.
Biochemical testing, DNA extraction and genotyping
Five milliliters of blood were obtained after overnight fast, collected in EDTA tubes, centrifuged at room temperature. Plasma glucose, cholesterol, HDL cholesterol, and triglyceride were determined by enzymatic methods as described by manufacturer’s instructions (Human, Wiesbaden, Germany). Genomic DNA was extracted from whole blood (300 μl) using genomic DNA purification kit QIAamp according to the manufacturer instructions (Qiagen, Hilden, Germany). DNA samples were stored at 4 °C for further analyses. Genotyping of the FTO rs9939609 SNP was done by PCR-based restriction fragment length polymorphism (RFLP) analysis as previously described [20] with the following modifications. The PCR reactions were carried out using 20 ng of purified genomic DNA samples, with 0.4 μM of the forward and reverse primers using PCR-Ready Supreme mix (Syntezza Bioscience, Jerusalem) in a final volume of 25 μl. The genotypes patterns were determined by 2% agarose gel electrophoresis (Agarose; Sigma-Aldrich, Munich, Germany) stained with Ethiduim bromide. A 5% masked, random sample of cases and controls were re-amplified and sent for sequencing to confirm the genotyping method.
Statistical analysis
The genotype frequencies were tested for Hardy–Weinberg equilibrium using a chi-square test through the website http://www.oege.org/software/hwe-mr-calc.html↗. All statistical analysis was performed using SPSS v23.0 (SPSS, Chicago, IL). Pearson’s Chi-square test was used to compare allelic and genotypic frequencies between the diabetic and nondiabetic groups. ANOVA was used to assess the association between FTO genotypes and continuous variables. Logistic regression by R statistics (V 3.4.4) software was used to measure odd ratio (OR) for T2DM adjusted for age, gender and BMI.
Results
Biochemical characteristics of the study participants
The biochemical and anthropometric results of the 281 T2DM patients and 118 nondiabetic subjects are shown in Table 1. As expected, significant differences in biochemical parameters was observed between the two groups (p < 0.05). However, the mean total cholesterol was not significant between diabetic and non diabetic groups (p = 0.25). Among T2DM group, 64.4% (n = 181) were obese (BMI > 30 kg/m2), 30.2% (n = 85) were overweight (25–29.9 kg/m2) and 5.3% (n = 15) were nonobese (BMI < 30 kg/m2). Of them, 76.6% were treated with oral hypoglycemic agent, 25.3% received a combination of insulin and oral hypoglycemic agents and 2.1% were treated with insulin. Of these patients, 14.6, 12.1, 7.8 and 6% had cardio vascular disease (CVD), nephropathy, diabetic foot and retinopathy, respectively. Noteworthy, 75% of the cases had T2DM first-degree relatives. Among the control group, 44.1% (n = 52) were obese, 22.9% (n = 27) were overweight and 33.1% (n = 39) were not obese.
| cases (=281)n | controls (=118)n | ||
|---|---|---|---|
| Parameters | P-value | ||
| M:F ratio | 94:187 | 48:70 | |
| Age at diagnosis (years) | 50.39+11.04 | NA | |
| Age at sampling (years) | 58.15±12.09 | 49.62±8.71 | 0.0001* |
| BMI | 32.9±6.6 | 29.2±6.2 | <0.0001* |
| SBP (mmHg) | 136.21±17.42 | 122.33±11.44 | 0.0001* |
| DBP (mmHg) | 80.21±10.83 | 76.72±9.37 | 0.0024* |
| FBS (mg/dl) | 163.31±58.72 | 87.14±7.82 | 0.0001* |
| TC (mg/dl) | 187.91±47.53 | 182.15±40.95 | 0.251 |
| Treatment (OHA,C,I)(n) | 204,71,6 | NA |
Analysis ofvariant FTO
FTO genotyping (rs9939609) was performed by PCR followed by RFLP. The presence of product was verified on a 2% agarose gel stained with ethidium bromide, a band of 187 bp was observed as shown in Fig. 1a. The PCR product was digested by ScaI restriction enzyme and visualized by 2% agarose gel. A band of 187 bp was observed for the TT genotype, two bands of 154, 33 bp was observed for the AA genotype while three bands of 187, 154, 33 bp were observed for the heterozygous genotype AT as shown in Fig. 1b.
Agarose gel electrophoresis (2%) ofgene variant () PCR products showing 187 bp amplicon (Lanes 1–5), lane 6: Negative control, lane 7: 50 bp ladder. () Digested PCR product representing different genotypes: Lanes 1, 3: AT genotype; Lanes 2, 5: AA genotype; Lane 4: TT genotype; Lane 7: 50 bp ladder FTO a b
Association ofvariant and T2DM FTO
The genotype and allele frequency of FTO gene polymorphism (rs9939609) a;mong the two groups were analyzed and compared as shown in Table 2. Our results revealed that carriers of AA genotype was significantly higher in T2DM subjects compared to non diabetic individuals (36%) vs (16%))(p = 0.003). The genotyping distribution was in line of Hardy Weinberg equilibrium in all cases and controls (p= > 0.05). Logistic regression analysis was performed for AT and AA genotypes with TT as a reference genotype. We found that the AT genotype conferred 2.1 times higher risk for T2DM compared to TT genotypes unadjusted p < 0.0001 (Table 3). As our controls were younger than diabetic cases, logistic regression model adjusted for age and gender was used, and showed that allelic odd ratio was 1.92 (95% CI [1.09–3.29], p = 0.02). This association remained significant even after adjusting for age, gender and BMI (OR 1.84, 95%CI (1.04–3.05)). The highest risk was observed among AA carriers compared to those with TT genotypes (OR 4.03, 95% CI (2.01–8.06) p < 0.0001) as shown in Table 3.
| Genotype | cases(n) | Controls (n) | All Subjects (n) |
|---|---|---|---|
| TT | 51 | 45 | 96 |
| AT | 129 | 54 | 183 |
| AA | 101 | 19 | 120 |
| A allele (%) | 58.8 | 38.9 | 53 |
| Genotype | OR( 95% CI ) | -valueP | OR(95% CI) | -value*P |
|---|---|---|---|---|
| AA vs TT | 4.69 (2.49–8.83) | <0.0001 | 4.03 (2.01–8.06) | <0.0001* |
| AT vs TT | 2.11 (1.26-3.52) | <0.0001 | 1.84 (1.04-3.05) | 0.034* |
| AA vs | ||||
| (AT+TT) | 2.78 (1.72-4.49) | <0.0001 | 2.71 (1.5-4.9) | 0.001* |
Association ofvariant with BMI FTO
The entire data including all the study subjects (n = 399) was stratified based on FTO genotypes, a significant association was found between FTO genotypes and mean BMI, the AA genotypes had the highest BMI (33.29 ± 7.2), unadjusted p = 0.03. Because of potential confounding between T2DM and increased BMI as proxy measure of obesity, the data was stratified by glycemic status across FTO genotypes. Among diabetic group, a trend of increasing mean BMI was observed among the three genotypes: AA carriers had the highest BMI (34.11 ± 7.1) compared to AT (32.32 ± 6.1) and TT carriers (31.86 ± 6.5) but it was not significant (p = 0.057). However, this increasing trend was not found among the control group (p = 0.7) as shown in Table 4. Furthermore, no association was found between the FTO genotype and gender, age, plasma total cholesterol, as well as systolic and diastolic blood pressure among the two groups. Among diabetic group, no association was found between the FTO genotype and cardio vascular disease or diabetes complications (p > 0.05).
| T2DM (=281)n | Control (=118)n | |||||||
|---|---|---|---|---|---|---|---|---|
| AA | AT | TT | -value*P | AA | AT | TT | -value*P | |
| Number | 101 | 129 | 51 | 19 | 54 | 45 | ||
| BMI (kg/m2) | 34.11±7.1 | 32.32±6.1 | 31.86±6.5 | 0.057 | 28.89±6.96 | 29.77±6.1 | 28.75±5.8 | 0.688 |
| SBP (mmHg) | 133.94±16.9 | 138.26±16.4 | 135.47±20.4 | 0.166 | 119.3±16.3 | 124.2±10.7 | 121.4±9.5 | 0.222 |
| DBP (mmHg) | 78.68±11.9 | 80.94±10.1 | 81.35±10.5 | 0.206 | 72.8±9.2 | 76.7±10.2 | 78.5±8.1 | 0.087 |
| FBS (mg/dl) | 159.11±54.3 | 163.97±58.9 | 169.94±65.6 | 0.553 | 85.9±6.9 | 87.7±7.4 | 86.9±8.8 | 0.693 |
| TC (mg/dl) | 189.16±49.3 | 188.57±49.2 | 183.71±39.8 | 0.783 | 168.1±40.1 | 188.5±48.8 | 180.4±28.2 | 0.165 |
Discussion
To our knowledge, this study is the first to investigate the association of the FTO variant rs9939609 with type 2 diabetes and BMI in Palestine. The significance of common variants in the FTO gene for susceptibility to adiposity have been highlighted by large-scale studies among Europeans while conflicting results were reported in Asian populations [21, 22]. Our study showed a significant association of FTO variant rs9939609 with T2DM after adjustment by age and gender with an allelic odds ratio of 1.92 (95% CI [1.09–3.29], p = 0.02). Moreover, we noted that the association of FTO variant rs9939609 with T2DM was partially attenuated by adjusting for BMI with odd ratio of 1.84, 95%CI (1.04–3.05) p = 0.03, suggesting that the FTO -T2DM association was not completely mediated through FTO variant effect on BMI. Similar results were found in Indian, American and Chinese populations [4, 10, 23]. Vasan and colleagues [24] provided evidence that FTO-T2DM risk -among Asian Indians- was attenuated but not fully abolished when adjusting to BMI. In contrast, a recent study conducted in Kuwaiti population did not observe an association between the FTO rs9939609 with T2DM risk [25]. Two studies in North Indians and Asian Indians demonstrated a strong association of FTO rs9939609 with T2DM independent of BMI [4, 26]. However, contradictory results for association of FTO variants with T2DM have been reported in different ethnic groups of India [27]. Furthermore, a meta-analysis study conducted in South Asia showed that BMI and central obesity can partly account for the association of A allele of the FTO gene and diabetes, whereas this association was much reduced when adjusted for BMI in Europeans indicating ethnic-specific associations [28]. On the other hand, several studies revealed a strong association between different variants within the FTO gene and BMI or diabetes supporting that the impact of FTO on obesity or diabetes is population-dependent [29–32]. A recent study conducted by Wang and colleagues [33] showed that FTO protein expression in T2DM patients was higher than in healthy controls which was positively correlated with T2DM severity, BMI and waist circumference.
Our study revealed that, among all study subjects, the TT carriers had lower BMI compared to AT and AA carriers (unadjusted p = 0.03) but when the mean BMI was stratified by glycemic status across FTO genotypes, the association with BMI was lost in the control group (p = 0.7). In diabetic group, an additive trend of the allele A with increased BMI was observed but was not significant (p = 0.057). However, further studies with larger sample size and greater statistical power are needed to replicate these findings. In 2016, a study conducted on Egyptian children and adolescents didn’t show an association between the polymorphism rs9939609 and BMI. However, that study revealed a significant correlation between LDL and FTO rs9939609 supporting the idea that this variant can be a determinant of obesity due to its effect on the lipid profile [34].
The high prevalence of obesity among our diabetic and control group (64 and 44%, respectively) could be attributed to other variants within FTO and or other genes which can be modulated by environmental factors and lifestyle. Anyhow, as our diabetic cases were older and had higher BMI than controls, we adjusted for the possible confounding effect of age, sex, and BMI in all the logistic regression analyses while investigating T2DM risk across FTO genotypes. Recently, a study conducted by Celis-Morales et al. [35] reported that physical activity attenuates the effect of FTO on BMI. Another study conducted on Emirati people showed that the AA carriers who were physically active had a lower mean BMI than those who were physically inactive, while other studies conducted on African Americans and Europeans showed no such interaction [36, 37]. Furthermore, a recent cross sectional study in a multiethnic population suggested that high dietary protein intake may protect against the effects of risk variants in the FTO gene on BMI and waist circumference [28]. In this study and due to the lack of data regarding physical activity or diet intake, we were unable to examine the influence of physical activity /diet on the impact of FTO variant on BMI. Although FTO -T2DM association was found, the lack of association between FTO rs9939609 and obesity is most probably due to the small sample size -and thereby decreased statistical power- which was the most important limitation in this study and thus larger sample size is required to verify these results. However, weight, skinfold thicknesses, body fat percentage and waist circumference are reported to be more reliable markers of obesity than BMI [38]. We believe that obesity-related genetic variants also modulate glucose–insulin secretion. Therefore, leaner cases should be recruited while investigating gene–T2DM association among Palestinians.
On the other hand, we did not find any association of FTO rs9939609 with the T2DM complications and the prevalence of CVD among the studied population. This is consistent with recent findings showing no association of FTO rs9939609 variant with diabetic retinopathy and nephropathy [39]. However, a meta-analysis study reported significant association of the FTO rs9939609 variant with CVD risk, which was independent of BMI and other conventional CVD risk factors [40].
Conclusion
The FTO rs9939609 variant was significantly associated with T2DM in Palestine. However, further analysis with larger sample size and data on physical activity and diet intake is required to elucidate the role of this variant and other variants of FTO gene on the predisposition to increased BMI in Palestinians.
Acknowledgments
The authors gratefully acknowledge the UNRWA outpatient clinic members (Hebron and Ramallah, Palestine) who contributed to the patients’ recruitment, and all subjects who participated to this study.
Funding
The deanship of scientific research-Al-Quds University provided the financial support.
Availability of data and materials
The data sets used and /or analyzed during the current study are available from the corresponding author upon reasonable request.
Abbreviations
Authors’ contributions
SE and AS performed the experiments and wrote the manuscript; SE and SC analyzed the data; AS, OA and MA collected the samples; AN and MI performed sequencing and analysis; SE, SC and AN designed and supervised the experiments, reviewed and revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All the study procedures were approved by the Ethics Committee of Al-Quds University (Rf no. 2/SRC/4).
Informed consent was obtained from all individual participants included in the study.
Consent for publication
Written consent was obtained from all participants to publish their data.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Anas Sabarneh, Email: anas_sabarnah@hotmail.com.
Suheir Ereqat, Phone: +972 569174033, Email: sereqat@staff.alquds.edu.
Stéphane Cauchi, Email: stephane.cauchi@ibl.cnrs.fr.
Omar AbuShamma, Email: abushamma_omar@yahoo.com.
Mohammad Abdelhafez, Email: mhafez1995@gmail.com.
Murad Ibrahim, Email: mibrahim@staff.alquds.edu.
Abdelmajeed Nasereddin, Email: abedn@ekmd.huji.ac.il.
References
Associated Data
Data Availability Statement
The data sets used and /or analyzed during the current study are available from the corresponding author upon reasonable request.